KLK3 and prostate carcinoma: Prostate-specific antigen recurrence (>0.2 ng ml−1) has been shown to be surrogate marker for prostate cancer-specific mortality from large, independent cohorts (Walsh et al, 1994; Zincke et al, 1994; Pound et al, 1999; D'Amico et al, 2003).